Key result
Percutaneous closure of the patent foramen ovale and left atrial appendage are reviewed as device-based therapies for stroke prevention in patients with cryptogenic stroke or atrial fibrillation.
This review discusses the role of percutaneous PFO and LAA closure devices in preventing cerebrovascular events in specific patient populations.
PFO and LAA closure techniques remain investigational; Level 5 data leaves open their net benefit versus medical therapy in stroke prevention.
Innovative percutaneous procedures for stroke prevention have emerged in the last two decades. Transcatheter closure of the patent foramen ovale (PFO) is performed in patients who suffered a cryptogenic stroke or a transient ischaemic attach (TIA) in order to prevent recurrence of thromboembolic events. Percutaneous occlusion of the left atrial appendage (LAA) has been introduced to reduce stroke risk in patients with atrial fibrillation (AF). The role of PFO and LAA in the occurrence of cerebrovascular events and the interventional device-based therapies to occlude the PFO and LAA are discussed.
No takes yet. Share an insight, caveat, or question.
Bartorelli et al. (2011) conducted a review in Stroke prevention, cryptogenic stroke, atrial fibrillation. Percutaneous closure of patent foramen ovale and left atrial appendage was evaluated. Percutaneous closure of the patent foramen ovale and left atrial appendage are reviewed as device-based therapies for stroke prevention in patients with cryptogenic stroke or atrial fibrillation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: